Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
70.57 USD | +0.28% | -2.62% | -1.19% |
Sales 2024 * | 137M 188M | Sales 2025 * | 158M 215M | Capitalization | 1.27B 1.73B |
---|---|---|---|---|---|
Net income 2024 * | 28M 38.27M | Net income 2025 * | 52M 71.08M | EV / Sales 2024 * | 9.23 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 8.04 x |
P/E ratio 2024 * |
42.2
x | P/E ratio 2025 * |
24.7
x | Employees | 58 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.16% |
Latest transcript on Ligand Pharmaceuticals Incorporated
1 day | +0.28% | ||
1 week | -2.62% | ||
Current month | -3.46% | ||
1 month | -0.98% | ||
3 months | -7.69% | ||
6 months | +42.36% | ||
Current year | -1.19% |
Managers | Title | Age | Since |
---|---|---|---|
Todd Davis
CEO | Chief Executive Officer | 63 | 07-02-28 |
Octavio Espinoza
DFI | Director of Finance/CFO | 53 | 22-10-31 |
President | 49 | 15-08-05 |
Members of the board | Title | Age | Since |
---|---|---|---|
John W. Kozarich
CHM | Chairman | 74 | 03-02-28 |
John LaMattina
BRD | Director/Board Member | 74 | 11-01-31 |
Stephen Sabba
BRD | Director/Board Member | 64 | 08-08-03 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.24% | 27 M€ | -5.03% | - | |
0.14% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 70.57 | +0.28% | 88,152 |
24-04-25 | 70.37 | -0.89% | 106,715 |
24-04-24 | 71 | +1.59% | 152,962 |
24-04-23 | 69.89 | +1.98% | 140,672 |
24-04-22 | 68.53 | -5.44% | 247,324 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.19% | 1.27B | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- LGND Stock